Get the Stockscreener App
0.776
2.28%
-0.0181
After Hours:
.78
0.004
+0.52%
Xilio Therapeutics Inc stock is traded at $0.776, with a volume of 347.65K.
It is down -2.28% in the last 24 hours and up +5.35% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.7941
Open:
$0.7983
24h Volume:
347.65K
Relative Volume:
0.63
Market Cap:
$40.22M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2622
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-5.89%
1M Performance:
+5.35%
6M Performance:
+9.45%
1Y Performance:
-3.12%
1-Day Range:
$0.7748
$0.8195
1-Week Range:
$0.7748
$0.8895
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.776 | 41.16M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Will Xilio Therapeutics Inc. stock remain a Wall Street favoriteWeekly Trend Report & Capital Efficiency Focused Strategies - newser.com
Can Xilio Therapeutics Inc. stock deliver sustainable ROEBull Run & Verified Trade Idea Suggestions - newser.com
Published on: 2025-10-13 01:22:44 - newser.com
Using AI based signals to follow Xilio Therapeutics Inc.Weekly Stock Recap & Growth Focused Entry Reports - newser.com
Using flow based indicators on Xilio Therapeutics Inc.July 2025 Spike Watch & Daily Market Momentum Tracking - newser.com
Xilio Therapeutics’ (XLO) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Is Xilio Therapeutics Inc. reversing from oversold territory2025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
Evaluating Xilio Therapeutics Inc. with trendline analysisJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Using R and stats models for Xilio Therapeutics Inc. forecastingJuly 2025 Rallies & Intraday High Probability Alerts - newser.com
How Xilio Therapeutics Inc. stock responds to policy changesPrice Action & Growth Focused Investment Plans - newser.com
Xilio Therapeutics Transfers Listing to Nasdaq Capital Market - The Globe and Mail
Xilio Therapeutics Announces Upcoming Presentations at the - GlobeNewswire
Xilio Therapeutics announces upcoming presentations at the Society for Immunotherapy of Cancer - MarketScreener
GlobeNewswire by Notified - The Manila Times
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - The Manila Times
Xilio Therapeutics Announces Multiple Poster Presentations at SITC 40th Annual Meeting Including Clinical Data for Vilastobart and XTX301 - Quiver Quantitative
3 Posters at SITC Nov 6-9, 2025: Xilio Presents vilastobart, XTX301 & Masked T Cell Engagers - Stock Titan
Xilio Therapeutics to transfer listing to Nasdaq Capital Market on Monday - Investing.com
Xilio Therapeutics transfers listing of co's common stock to Nasdaq Capital Market - MarketScreener
Detecting support and resistance levels for Xilio Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Has Xilio Therapeutics Inc. found a price floorTrade Exit Summary & Reliable Intraday Trade Alerts - newser.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
26,000-Share Grant: Xilio Therapeutics Grants Options at $0.8326 Exercise Price - Stock Titan
Xilio Therapeutics Inc Stock Analysis and ForecastVolatility Index Analysis & AI Alerts You Can Actually Trust - earlytimes.in
What analysts say about Xilio Therapeutics Inc stockAnalyst Upgrades & Investment Timing Techniques - Early Times
What drives Xilio Therapeutics Inc stock priceResistance Breakout Alerts & Low Cost Stock Picks - Early Times
Applying chart zones and confluence areas to Xilio Therapeutics Inc.Quarterly Trade Summary & Verified Momentum Stock Ideas - newser.com
Detecting price anomalies in Xilio Therapeutics Inc. with AI2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.8% – What’s Next? - Defense World
Published on: 2025-09-21 20:25:05 - newser.com
Is Xilio Therapeutics Inc. a candidate for recovery playQuarterly Portfolio Summary & Daily Entry Point Alerts - newser.com
Can Xilio Therapeutics Inc expand into new marketsJuly 2025 Recap & Short-Term Trading Opportunity Alerts - خودرو بانک
Update Recap: Is Xilio Therapeutics Inc stock forming a cup and handle2025 Market Outlook & Real-Time Volume Trigger Notifications - خودرو بانک
Ranking Xilio Therapeutics Inc. among high performing stocks via tools2025 Price Targets & Scalable Portfolio Growth Ideas - newser.com
Is Xilio Therapeutics Inc. showing signs of accumulationVolume Spike & Verified Chart Pattern Signals - newser.com
Fed Meeting: How much upside does Xilio Therapeutics Inc haveTrade Volume Summary & Daily Oversold Bounce Ideas - khodrobank.com
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xilio Therapeutics Inc Stock (XLO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director |
Jun 17 '25 |
Buy |
0.69 |
25,000 |
17,215 |
70,000 |
| Russo Rene | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
0.68 |
36,289 |
24,680 |
281,172 |
| Frankenfield Christopher James | Chief Financial Officer |
Jan 02 '25 |
Sale |
0.98 |
6,954 |
6,841 |
12,421 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):